Cargando…

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment

We previously identified an extracellular matrix (ECM) gene expression pattern in breast cancer (BC), called ECM3, characterized by a high expression of genes encoding structural ECM proteins. Since ECM is reportedly implicated in response to therapy of BCs, the aim of this work is to investigate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rybinska, Ilona, Sandri, Marco, Bianchi, Francesca, Orlandi, Rosaria, De Cecco, Loris, Gasparini, Patrizia, Campiglio, Manuela, Paolini, Biagio, Sfondrini, Lucia, Tagliabue, Elda, Triulzi, Tiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072535/
https://www.ncbi.nlm.nih.gov/pubmed/32069815
http://dx.doi.org/10.3390/cells9020434
_version_ 1783506429047472128
author Rybinska, Ilona
Sandri, Marco
Bianchi, Francesca
Orlandi, Rosaria
De Cecco, Loris
Gasparini, Patrizia
Campiglio, Manuela
Paolini, Biagio
Sfondrini, Lucia
Tagliabue, Elda
Triulzi, Tiziana
author_facet Rybinska, Ilona
Sandri, Marco
Bianchi, Francesca
Orlandi, Rosaria
De Cecco, Loris
Gasparini, Patrizia
Campiglio, Manuela
Paolini, Biagio
Sfondrini, Lucia
Tagliabue, Elda
Triulzi, Tiziana
author_sort Rybinska, Ilona
collection PubMed
description We previously identified an extracellular matrix (ECM) gene expression pattern in breast cancer (BC), called ECM3, characterized by a high expression of genes encoding structural ECM proteins. Since ECM is reportedly implicated in response to therapy of BCs, the aim of this work is to investigate the prognostic and predictive value of ECM3 molecular classification in HER2-positive BCs. ECM3 resulted in a robust cluster that identified a subset of 25–37% of HER2-positive tumors with molecular aggressive features. ECM3 was significantly associated with worse prognosis in two datasets of HER2-positive BCs untreated with adjuvant therapy. Analyses carried out on two of our cohorts of patients treated or not with adjuvant trastuzumab showed association of ECM3 with worse prognosis only in patients not treated with trastuzumab. Moreover, investigating a dataset that includes gene profile data of tumors treated with neoadjuvant trastuzumab plus chemotherapy or chemotherapy alone, ECM3 was associated with increased pathological complete response if treated with trastuzumab. In the in vivo experiments, increased diffusion and trastuzumab activity were found in tumors derived from injection of HER2-positive cells with Matrigel that creates an ECM-rich tumor environment. Taken together, these results indicate that HER2-positive BCs classified as ECM3 have an aggressive phenotype but they are sensitive to trastuzumab treatment.
format Online
Article
Text
id pubmed-7072535
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70725352020-03-19 Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment Rybinska, Ilona Sandri, Marco Bianchi, Francesca Orlandi, Rosaria De Cecco, Loris Gasparini, Patrizia Campiglio, Manuela Paolini, Biagio Sfondrini, Lucia Tagliabue, Elda Triulzi, Tiziana Cells Article We previously identified an extracellular matrix (ECM) gene expression pattern in breast cancer (BC), called ECM3, characterized by a high expression of genes encoding structural ECM proteins. Since ECM is reportedly implicated in response to therapy of BCs, the aim of this work is to investigate the prognostic and predictive value of ECM3 molecular classification in HER2-positive BCs. ECM3 resulted in a robust cluster that identified a subset of 25–37% of HER2-positive tumors with molecular aggressive features. ECM3 was significantly associated with worse prognosis in two datasets of HER2-positive BCs untreated with adjuvant therapy. Analyses carried out on two of our cohorts of patients treated or not with adjuvant trastuzumab showed association of ECM3 with worse prognosis only in patients not treated with trastuzumab. Moreover, investigating a dataset that includes gene profile data of tumors treated with neoadjuvant trastuzumab plus chemotherapy or chemotherapy alone, ECM3 was associated with increased pathological complete response if treated with trastuzumab. In the in vivo experiments, increased diffusion and trastuzumab activity were found in tumors derived from injection of HER2-positive cells with Matrigel that creates an ECM-rich tumor environment. Taken together, these results indicate that HER2-positive BCs classified as ECM3 have an aggressive phenotype but they are sensitive to trastuzumab treatment. MDPI 2020-02-13 /pmc/articles/PMC7072535/ /pubmed/32069815 http://dx.doi.org/10.3390/cells9020434 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rybinska, Ilona
Sandri, Marco
Bianchi, Francesca
Orlandi, Rosaria
De Cecco, Loris
Gasparini, Patrizia
Campiglio, Manuela
Paolini, Biagio
Sfondrini, Lucia
Tagliabue, Elda
Triulzi, Tiziana
Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
title Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
title_full Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
title_fullStr Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
title_full_unstemmed Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
title_short Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
title_sort extracellular matrix features discriminate aggressive her2-positive breast cancer patients who benefit from trastuzumab treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072535/
https://www.ncbi.nlm.nih.gov/pubmed/32069815
http://dx.doi.org/10.3390/cells9020434
work_keys_str_mv AT rybinskailona extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT sandrimarco extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT bianchifrancesca extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT orlandirosaria extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT dececcoloris extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT gasparinipatrizia extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT campigliomanuela extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT paolinibiagio extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT sfondrinilucia extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT tagliabueelda extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment
AT triulzitiziana extracellularmatrixfeaturesdiscriminateaggressiveher2positivebreastcancerpatientswhobenefitfromtrastuzumabtreatment